GW Pharmaceuticals and Jazz Pharmaceuticals will build a new manufacturing facility in Kent Science Park, Sittingbourne. The facility will produce two cannabis-based drugs as well as new drugs. Production is scheduled to begin in 2024. The investment will be $100 million.

Jazz Pharmaceuticals has completed its merger with GW Pharmaceuticals. GW Pharmaceuticals shareholders received $220 for each depositary receipt representing 12 common shares of the company. Of that, $200 in cash and $20 in Jazz common stock.

GW Pharmaceuticals has received approval from the European Commission for the use of Epidyolex, a cannabis-based drug, as an adjunctive treatment for seizures in children 2 years and older.

GW Pharmaceuticals' GAAP loss for 2020 was $58.128 million, up 6.4 times from $9.019 million in the previous year. Revenue increased 69.3% to $527.205 million, up from $311.332 million a year earlier.